Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
131
datasets available to search
ShareScore release 0.9.0
Dataset results
131 results for “crossover trial”
Pharmacodynamics parameters underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
<p><b>Background</b>: Empagliflozin is an SGLT2 inhibitor approved for use in patients with Diabetes Mellitus type 2 (DMT2) with- or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed<b> </b>to determine the chronopharmacological effects of morning vs evening administration of empagliflozin 10 mg in Healthy Egyptian adults, by investigating the pharmacokinetics and pharmacodynamics parameters of empagliflozin depending on the intake time. </p> <p><b>Methods: </b>An open label, sequential, two‐way crossover trial comprised two periods with a washout period of 7 days. Pharmacokinetics parameters (t<sub>max</sub> (h), C<sub>max</sub> (ng/ml), AUC <sub>0-t</sub> (ng.h/ml)) as primary endpoints, and (AUC <sub>0 to ∞</sub>(ng.h/ml)) as secondary endpoint were assessed. Method validation was done prior to injection in LC/MS/MS and samples were processed by Liquid-Liquid extraction. The pharmacodynamic profile (UGE <sub>0-24</sub>) was determined after method validation (glucose hexokinase method).</p> <p><b>Results: </b>T<sub>max</sub> increased by (35%) in the evening phase compared to the morning phase, while C<sub>max</sub> decreased by (-6.5%)in the evening dose compared to the morning dose. Besides, AUC<sub>0 to ∞</sub> increased in the evening phase by (8.25%) compared to the morning phase. The mean cumulative amount of glucose excreted; UGE (<sub>0-24</sub>) increased by (43%) in the evening dose compared to the morning dose</p> <p><strong>Conclusion: </strong>Despite there was a significant difference between morning and evening doses, it didn't reach the significant level, thus, it can be concluded that there is no difference between the morning and evening doses.</p>
Data from: Use of the lung flute ECO to assist in sputum collection for tuberculosis testing: a randomized crossover trial
<p>The Lung Flute ECO, a self-powered, low cost, oscillatory positive expiratory pressure (OPEP) device, assisted people with presumptive tuberculosis to produce an adequate sputum volume for diagnostic testing and was well-tolerated.</p>
Video supplement to "A randomized, controlled, crossover trial of median nerve stimulation for treatment of Tourette syndrome"
<p>Video from the last 60 s of Block 5 (stimulation off) and the first 60 s of Block 6 (stimulation on) from the rhythmic <span class="math-tex">\(\pm \)</span> arrhythmic visits of three study participants who reported substantial improvement in tic severity on at least one visit.</p>
CES1 Crossover Trial of Clopidogrel and Ticagrelor
ClinicalTrials.gov study NCT03161678. IPD Sharing: YES. Countries: 1. Publications: 0.
A Prospective Cluster-Randomized, Controlled Crossover Trial to Validate an Electronic "Resistance Calculator"
ClinicalTrials.gov study NCT05304221. IPD Sharing: NO. Countries: 1. Publications: 10.
Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension
ClinicalTrials.gov study NCT02412761. IPD Sharing: NO. Countries: 1. Publications: 2.
A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis
ClinicalTrials.gov study NCT00913692. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Replicate Crossover Trial on Nutritional Supplementation in Association Football (Soccer)
ClinicalTrials.gov study NCT07190989. IPD Sharing: NO. Countries: 1. Publications: 55.
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteer
ClinicalTrials.gov study NCT02631954. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ClinicalTrials.gov study NCT05259917. IPD Sharing: NO. Countries: 21. Publications: 3.
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
ClinicalTrials.gov study NCT01161563. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Management During Labor: A Crossover Clinical Trial.
ClinicalTrials.gov study NCT07401147. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Crossover Trial of AD036 in Obstructive Sleep Apnea
ClinicalTrials.gov study NCT04445688. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Protocol, case report(s), ethics approvals, informed consent, inclusion and exclusion criteria underlying: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
Open the record for dataset details and reuse information.
Data from: Use of the lung flute ECO to assist in sputum collection for tuberculosis testing: a randomized crossover trial
Open the record for dataset details and reuse information.
Pharmacokinetics parameters, bioanalytical method underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover non-randomised trial
Open the record for dataset details and reuse information.
Pharmacodynamics parameters underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
Open the record for dataset details and reuse information.
Data from: BCI training to move a virtual hand reduces phantom limb pain: a randomized crossover trial
<p>Objective: To determine whether training with a brain–computer interface (BCI) to control an image of a phantom hand, which moves based on cortical currents estimated from magnetoencephalographic signals, reduces phantom limb pain.</p> <p>Methods: Twelve patients with chronic phantom limb pain of the upper limb due to amputation or brachial plexus root avulsion participated in a randomized single-blinded crossover trial. Patients were trained to move the virtual hand image controlled by the BCI with a real decoder, which was constructed to classify intact hand movements from motor cortical currents, by moving their phantom hands for 3 days ("real training"). Pain was evaluated using a visual analogue scale (VAS) before and after training, and at follow-up for an additional 16 days. As a control, patients engaged in the training with the same hand image controlled by randomly changing values ("random training"). The two trainings were randomly assigned to the patients. This trial is registered at UMIN-CTR (UMIN000013608).</p> <p>Results: VAS at day 4 was significantly reduced from the baseline after real training (45.3 [24.2] to 30.9 [20.6], 1/100mm, mean [SDs]; P=0.009<0.025), but not after random training (P=0.047>0.025). Compared to VAS at day 1, VAS at days 4 and 8 was significantly reduced by 32% and 36%, respectively, after real training and was significantly lower than VAS after random training (P<0.01).</p> <p>Conclusion: Three-day training to move the hand images controlled by BCI significantly reduced pain for one week.<br> Classification of evidence: This study provides Class &#8546; evidence that BCI reduces phantom limb pain.</p> <p> </p>
Data set from: Robot-Assisted Gait Training in Patients with Multiple Sclerosis: A Randomized Controlled Crossover Trial.
<p>Data set from the paper "Robot-Assisted Gait Training in Patients with Multiple Sclerosis: A Randomized Controlled Crossover Trial" doi: <a href="https://dx.doi.org/10.3390%2Fmedicina57070713">10.3390/medicina57070713</a></p>
Neuromodulation of premotor and posterior parietal cortices for enhancing explicit motor sequence learning in healthy individuals: a randomized, sham-controlled crossover trial
<p>Data collected and analysed in the manuscript '<strong>Neuromodulation of premotor and posterior parietal cortices for enhancing explicit motor sequence learning in healthy individuals: a randomized, sham-controlled crossover trial', </strong>by Russo et al. PPCR. The Principles and Practice of Clinical Research, 2021</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.